Vaccine Development to Treat Alzheimer’s Disease Neuropathology in APP/PS1 Transgenic Mice
Figure 6
Quantification of IgG antibodies against beta-amyloid and Th1/Th2 cytokine detection after immunization. (a) Presence of anti-β-amyloid in the sera of EB101-vaccinated and control transgenic mice groups after preventive and therapeutic treatment. EB101 led to a quite high increase of IgG antibody production as shown. ELISA was used for sera antibody detection in mice in each group. Each bar represents the background OD mean value ± SEM in each group. (b) Proliferative response of spleen cells from EB101-treated mice and controls after preventive and therapeutic treatment. Results showed that both EB101 and LPS induced B and T lymphocyte proliferative responses. Note that EB101 treatment resulted in an enhanced proliferation response when compared with EB102 and PBS control mouse groups (). The results obtained from triplicate assays were expressed as stimulation indices (ratio between mean OD ± SEM from stimulated and unstimulated cultures). (c) Detection of Th1 and Th2 cytokines in transgenic mice after therapeutic treatment. Analysis of variance (ANOVA) for IL-5, -6, -10, and -13 indicated significant differences between vaccinated and control groups. Results are shown as mean pg/mL ± SEM.
